PMID- 34349358
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210806
IS  - 0968-7637 (Print)
IS  - 0968-7637 (Linking)
VI  - 28
IP  - 3
DP  - 2021
TI  - People of color in North America report improvements in racial trauma and mental 
      health symptoms following psychedelic experiences.
PG  - 215-226
LID - 10.1080/09687637.2020.1854688 [doi]
AB  - This study examined how psychedelics reduced symptoms of racial trauma among 
      black, indigenous, and people of color (BIPOC) subsequent to an experience of 
      racism. A cross-sectional internet-based survey included questions about 
      experiences with racism, mental health symptoms, and acute and enduring 
      psychedelic effects. Changes in mental health were assessed by retrospective 
      report of symptoms in the 30 days before and 30 days after an experience with 
      psilocybin, Lysergic acid diethylamide (LSD), or 
      3,4-Methylenedioxymethamphetamine (MDMA). We recruited 313 diverse BIPOC in the 
      US and Canada. Results revealed a significant (p < .001) and moderate (d = -.45) 
      reduction in traumatic stress symptoms from before-to-after the psychedelic 
      experience. Similarly, participants reported decreases in depression (p < .001; d 
      = -.52), anxiety (p < .001; d = -.53), and stress (p < .001; d = -.32). There was 
      also a significant relationship (R(c) = 0.52, p < .001) between the dimension of 
      acute psychedelic effects (mystical-type, insight, and challenging experiences) 
      and decreases in a cluster of subsequent psychopathology (traumatic stress, 
      depression, anxiety, and stress), while controlling for the frequency of prior 
      discrimination and the time since the psychedelic experience. BIPOC have been 
      underrepresented in psychedelic studies. Psychedelics may decrease the negative 
      impact of racial trauma. Future studies should examine the efficacy of 
      psychedelic-assisted therapy for individuals with a history of race-based trauma.
FAU - Williams, Monnica T
AU  - Williams MT
AUID- ORCID: 0000-0003-0095-3277
AD  - School of Psychology, University of Ottawa, Ottawa, Canada.
AD  - Department of Psychological Sciences, University of Connecticut, Storrs, CT, USA.
FAU - Davis, Alan K
AU  - Davis AK
AD  - College of Social Work, The Ohio State University, Columbus, OH, USA.
AD  - Center for Psychedelic and Consciousness Research, Department of Psychiatry and 
      Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
FAU - Xin, Yitong
AU  - Xin Y
AD  - College of Social Work, The Ohio State University, Columbus, OH, USA.
FAU - Sepeda, Nathan D
AU  - Sepeda ND
AD  - Center for Psychedelic and Consciousness Research, Department of Psychiatry and 
      Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA.
FAU - Grigas, Pamela Colomicronn
AU  - Grigas PC
AD  - Department of Psychological Sciences, University of Connecticut, Storrs, CT, USA.
FAU - Sinnott, Sinead
AU  - Sinnott S
AD  - Department of Psychological Sciences, University of Connecticut, Storrs, CT, USA.
FAU - Haeny, Angela M
AU  - Haeny AM
AD  - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
LA  - eng
GR  - R25 DA035163/DA/NIDA NIH HHS/United States
GR  - T32 DA019426/DA/NIDA NIH HHS/United States
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20201210
PL  - England
TA  - Drugs (Abingdon Engl)
JT  - Drugs (Abingdon, England)
JID - 9515845
PMC - PMC8330400
MID - NIHMS1664570
OTO - NOTNLM
OT  - Psychedelics
OT  - ethnic minorities
OT  - hallucinogens
OT  - people of color
OT  - racial trauma
OT  - substance use
EDAT- 2021/08/06 06:00
MHDA- 2021/08/06 06:01
PMCR- 2021/08/03
CRDT- 2021/08/05 06:21
PHST- 2021/08/05 06:21 [entrez]
PHST- 2021/08/06 06:00 [pubmed]
PHST- 2021/08/06 06:01 [medline]
PHST- 2021/08/03 00:00 [pmc-release]
AID - 10.1080/09687637.2020.1854688 [doi]
PST - ppublish
SO  - Drugs (Abingdon Engl). 2021;28(3):215-226. doi: 10.1080/09687637.2020.1854688. 
      Epub 2020 Dec 10.